Clinical significances and distribution of unexpected antibodies found in infants
This study aims to analyze the pattern of unexpected antibodies and their clinical significance in infants. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 20, 2023 Category: Hematology Authors: Han Joo Kim, Suk Won Seo, Yousun Chung, Hyungsuk Kim, Sang-Hyun Hwang, Heung-Bum Oh, Dae-Hyun Ko Source Type: research
Global Burden of Transfusion in Sickle Cell Disease
Sickle cell disease (SCD) is the most common hereditary hemoglobinopathy. The underlying pathophysiology of the red blood cell (RBC) leads to pan-systemic complications which manifest at an early age. While curative and disease-modifying treatments exist for SCD, a key intervention in the management and treatment of SCD is RBC transfusion, which can alleviate or prevent many complications. SCD patients often require chronic RBC transfusion therapy which can result in complications, such as iron overload, alloimmunization and infection. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 17, 2023 Category: Hematology Authors: Baba PD Inusa, Wale Atoyebi, Biree Andemariam, James N Hourani, Laurel Omert Source Type: research
A Report from the SIdEM: Italy
Dear Colleagues and friends (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 14, 2023 Category: Hematology Authors: Angelo Ostuni, Patrizia Accorsi, Alessandro Mazzoni, Michele Vacca, Anna Colpo, Vanessa Agostini, Giovanni Crovetti, Ornella Iuliani, Anna Michelotti, Maria Beatrice Rondinelli, Alberto Zanella, Carlo Antozzi, Giustina De Silvestro, Francesco Lanza, Mauro Source Type: research
Opportunities to Share Information
When this journal, Transfusion and Apheresis Science, became the official journal of the World Apheresis Association, the agreement between the publisher and the WAA involved a commitment that there would be an allocation of dedicated space to allow publication of information important to the apheresis community but which was not in the format of a standard scientific presentation. One of the sections dedicated to this purpose in the Journal is the Listening Post which was designed to communicate information considered specifically relevant to the operators and nurses. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 10, 2023 Category: Hematology Authors: Gail Rock Source Type: research
The listening post
When this journal, Transfusion and Apheresis Science, became the official journal of the World Apheresis Association, the agreement between the publisher and the WAA involved a commitment that there would be an allocation of dedicated space to allow publication of information important to the apheresis community but which was not in the format of a standard scientific presentation. One of the sections dedicated to this purpose in the Journal is the Listening Post which was designed to communicate information considered specifically relevant to the operators and nurses. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 10, 2023 Category: Hematology Authors: Gail Rock Source Type: research
Variable Recovery of Cryopreserved Hematopoietic Stem Cells and Leukocyte Subpopulations in Leukapheresis Products
Due to the expansion of cell therapy using not only haematopoietic stem cells (HSC) but also other leukocyte subpopulations, the loss of these cells in cryopreserved apheresis products needs to be evaluated. Various factors that could negatively affect post-thaw recovery, such as leukapheresis product characteristics, storage time and cryopreservation protocols have been identified. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 8, 2023 Category: Hematology Authors: Vladimira Rimac, Ines Bojani ć, Sanja Dabelić, Branka Golubić Ćepulić Source Type: research
Efforts to recruit and enhance blood donor return probability: A point of view from Oslo, Norway
Transfusion of human blood remains irreplaceable in human medicine and we need to pave the ground for continued and sustainable action in the decades to come. Blood and transfusion services around the world currently experience challenges and need to increase donor recruitment and retention. This invited commentary focuses on the foundation and maintenance of a functional transfusion service for the coming years as it is imperative to develop and continuously reappraise the blood supply and transfusion service, based on evidence, experience and expertise, to meet expected and unexpected requirements of the future. (Source:...
Source: Transfusion and Apheresis Science - July 7, 2023 Category: Hematology Authors: Lise Sofie H Nissen-Meyer Source Type: research
Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use
Four-factor prothrombin complex concentrate (4F-PCC) may be an option for patients with bleeding unrelated to therapeutic anticoagulation to help with bleeding cessation and reduce blood component requirements. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 5, 2023 Category: Hematology Authors: Elizabeth Uttaro, Mikaela R. Young, Jennifer Falvey, Jenna M. Corvelli, Nicole M. Acquisto Source Type: research
Collection Efficiency in Apheresis
This report summarizes classical and novel CE analyses applied to apheresis exemplified by an actual case of hematopoietic progenitor cell collection. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 5, 2023 Category: Hematology Authors: Yandy Marx Castillo-Aleman, Yendry Ventura-Carmenate, May Ann-Martinez Source Type: research
A rare report of H-partially deficient, non-secretor phenotype from India. An Ah like the r èunion and unlike a Para Bombay- Clarifying misinterpretations.
H-deficient phenotypes are classified as H-deficient non- secretors (Bombay Oh), H-deficient secretors (Para Bombay), and H-partially deficient non-secretors (O h reunion, Ah and Bh, ABh). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 3, 2023 Category: Hematology Authors: Yashaswi Dhiman, Hem Chandra Pandey, Gopal Patidar, Manish Raturi, Bhawana Adhikari, Ashwani Bhat, Dushyant Singh Gaur Tags: Case Report Source Type: research
CAR-T cells, the first pharmaceutical cell therapy
The success of genetically engineered adoptive cell therapies in haematological malignancy in the second decade of the 21st century has surprised both immunologists and oncologists. It challenges much of our understanding of the role of personalised medicine, the divide between cell products and pharmaceutical drugs and the limitations of the immune system to clear cancer. Furthermore, many challenges remain, the therapy is both expensive, hazardous and largely restricted to lymphoproliferative disease. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - June 27, 2023 Category: Hematology Authors: Arian Laurence Tags: Review Source Type: research
CAR-T cells, the first pharmaceutical cell therapy.
The success of genetically engineered adoptive cell therapies in haematological malignancy in the second decade of the 21st century has surprised both immunologists and oncologists. It challenges much of our understanding of the role of personalised medicine, the divide between cell products and pharmaceutical drugs and the limitations of the immune system to clear cancer. Furthermore, many challenges remain, the therapy is both expensive, hazardous and largely restricted to lymphoproliferative disease. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - June 27, 2023 Category: Hematology Authors: Arian Laurence Tags: Review Source Type: research
Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis
Anemia is a common symptom of hematological malignancies and red blood cell (RBC) transfusion is the primary supportive treatment, with many patients becoming transfusion dependent. Hemanext Inc. (Lexington, MA, United States) has developed a CE mark certified device to process and store RBCs hypoxically – citrate-phosphatedextrose (CPD)/phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) RBCs, leukocytes-reduced (LR), O2/CO2 reduced – with the aim of improving RBC quality for transfusion. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - June 21, 2023 Category: Hematology Authors: H åkon Reikvam, Geir Hetland, Farshid Ezligini, Kim Dorsch, Laurel Omert, Andrew Dunham, Stian K Almeland Source Type: research
Seroprevalence of Trypanosoma cruzi infection among blood donors in the state of Par á, Brazil
Chagas disease (CD) is a neglected pathology worldwide, considered a public health problem due to the high morbidity and mortality rate and its social impact. Thus, the objective was to estimate the prevalence of reactive serology for T. cruzi in blood donors in the units of the public blood network in the state of Par á (Brazil), as well as to describe the epidemiological profile of these donors. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - June 21, 2023 Category: Hematology Authors: Jade Dias Valente, Nat ália da Silva Silva, Sthefany Vasconcelos de Sousa, Carlos Eduardo de Melo Amaral, Laine Celestino Pinto Source Type: research
Survey on the usage of Therapeutic Erythrocytapheresis in Transfusion Services in Italy for the treatment of Polycythemia Vera, secondary Erythrocytosis and Hemochromatosis.
Erythrocytapheresis, an apheresis treatment which selectively removes red blood cells, is an alternative to therapeutic phlebotomy, over which it has several advantages.Actually there is a high degree of variability in the use of this treatment. This prompted SIdEM (Italian Society of Hemapheresis and Cell Manipulation) to conduct a survey on the use of erythrocytapheresis in the Italian Transfusion Services. The purpose is to monitor this activity in the treatment of Polycythemia Vera (pv), secondary erythrocytosis and hemochromatosis. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - June 20, 2023 Category: Hematology Authors: O. Iuliani, C. Passeri, G. Inghilleri, E. Di Bartolomeo, L. Abbruzzese, I. Bianco, M.L. Foddai, G.A. Natale, G. De Fusco, M. D ’Onofrio, M.G. Fadda, A. Dominijanni, C. Savignano, A. Ostuni Source Type: research
